
|Videos|August 3, 2021
Complementary use of mpMRI and genomic testing in prostate cancer
Author(s)Urology Times staff
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.
Advertisement
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
From GSM guidance to HRT reform: A landmark year for women’s health
2
What’s new at Urology on the Beach 2026
3
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
4
Adjusted EV-302 analysis reinforces survival advantage of EV/pembrolizumab
5




















